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ABSTRACT
Introduction: Critically ill patients and their pharmacokinetics present complexities often not considered by consensus guidelines from
the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases
Pharmacists. Prior surveys have suggested discordance between certain guideline recommendations and reported infectious disease pharmacist practice. Vancomycin dosing practices, including institutional considerations, have not previously been well described in the critically
ill patient population.
Objectives: To evaluate critical care pharmacists’ self-reported vancomycin practices in comparison to the 2009 guideline recommendations and other best practices identified by the study investigators.
Methods: An online survey developed by the Research and Scholarship Committee of the Clinical Pharmacy and Pharmacology (CPP)
Section of the Society of Critical Care Medicine (SCCM) was sent to pharmacist members of the SCCM CPP Section practicing in adult intensive care units in the spring of 2017. This survey queried pharmacists’ self-reported practices regarding vancomycin dosing and monitoring
in critically ill adults.
Results: Three-hundred and sixty-four responses were received for an estimated response rate of 26%. Critical care pharmacists selfreported largely following the 2009 vancomycin dosing and monitoring guidelines. The largest deviations in guideline recommendation compliance involve consistent use of a loading dose, dosing weight in obese patients, and quality improvement efforts related to systematically
monitoring vancomycin-associated nephrotoxicity. Variation exists regarding pharmacist protocols and other practices of vancomycin use in
critically ill patients.
Conclusion: Among critical care pharmacists, reported vancomycin practices are largely consistent with the 2009 guideline recommendations. Variations in vancomycin dosing and monitoring protocols are identified, and rationale for guideline non-adherence with loading
doses elucidated.
Keywords: Vancomycin, critical care, therapeutic drug monitoring, guideline, continuous infusion, dose, monitoring
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Introduction

From 2009-2020, guidelines for vancomycin dosing were available through a joint effort from the American Society of
Health-System Pharmacists (ASHP), the Infectious Diseases
Society of America (IDSA), and the Society of Infectious
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Diseases Pharmacists (SIDP).1 Despite availability of these
guidelines and over 50 years of clinical experience, much
remains unknown regarding the optimal use of vancomycin in
clinical practice.2 A 2013 survey of infectious diseases pharmacists revealed discordance between vancomycin practices and
guideline recommendations, particularly regarding a reluctance
to use loading doses in seriously ill patients, to use actual body
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weight for dose calculation in obesity, and to systematically
monitor for complications such as nephrotoxicity.3
The compliance of pharmacists and physicians with guideline
recommendations for vancomycin dosing and monitoring is
important from an overall antimicrobial stewardship perspective,
but is of particular importance in the critical care setting for several reasons. The complexities of the intensive care unit (ICU)
patient population introduce additional challenges to a complex
drug. The acuity of the patient population demands adequate
pharmacokinetic-pharmacodynamic target attainment for serious, life-threatening infections while minimizing the risk of
nephrotoxicity for patients already at risk of acute kidney injury
and often simultaneously prescribed multiple other nephrotoxins. Critically ill patients’ clearance of vancomycin could vary,
from significant decreases in acute kidney injury to clinically significant increases in the setting of augmented renal clearance.
Adjustments for other medical therapies, such as continuous
renal replacement therapy (CRRT) and other dialysis modalities, represent unique circumstances that may not be addressed
by guidelines. Other “best practice” items related to vancomycin
dosing in the critically ill are likely variable across ICU pharmacists due to unique aspects of this patient population.
If any discordant areas of practice deviate in a substantial way
from guideline recommendations, understanding factors driving
critical care pharmacists’ decisions to do so are important to elucidate and represent cornerstones of implementation science efforts.
The purpose of this survey was to determine if this variability
exists in an effort to potentially inform future guideline recommendations and to reduce variability in evidence-based practices.
We sought to build on a prior survey of vancomycin use3 in the
following ways: (1) To perform a more recent survey of practice
patterns given the continuously updated literature on vancomycin
since 2013, (2) To study under which clinical scenarios ICU pharmacists may not adhere to guideline recommendations and ascertain why, (3) To characterize practice patterns regarding
ICU-centric dosing challenges that may not be addressed in consensus guidelines, and (4) To explore respondent characteristics
associated with compliance to guideline recommendations or
early adoption of certain vancomycin dosing practices.

Materials and methods
Survey design
A survey was developed by a pharmacist working group of the
Society of Critical Care Medicine (SCCM) Clinical Pharmacy
and Pharmacology (CPP) Research and Scholarship Committee
in early 2017. This survey was approved by the University of
Kentucky Institutional Review Board as an exempt study.
Survey questions were developed by the working group using
the 2009 ASHP/IDSA/SIDP guidelines as a template.1 Once
guideline recommendations were addressed in the survey, additional survey questions were created to capture areas of what the
authors considered “best practice” or areas where substantial
variability in practice was hypothesized to exist; for example,
whether pharmacists were alerted to initiation or
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discontinuation of renal replacement therapies to adjust dosing
accordingly. The survey was a 24-item questionnaire, with six
general demographic questions, eight vancomycin-related
demographic questions regarding the practice site, and 10 questions related to individual clinician’s vancomycin dosing practices (Appendix).
A modified Likert scale was used: rarely (<10% of the
time); sometimes (10-50% of the time); often (51-90% of the
time); and routinely (>90% of the time) was used for questions
of which a frequency of a particular action was inquired (eg.
how often a clinician would recommend an intervention). A
pilot survey was performed by five non-critical care pharmacists to establish face and content validity of the survey instrument. Six critical care pharmacists not involved on the study
team took the survey to estimate time required for completion
and provide any additional feedback or areas for clarification.
Verbal and written feedback from all pilot tests were incorporated into the final survey by the research team. The survey
required approximately 10-15 minutes for completion.

Cross-sectional survey
Invitations to complete the survey were sent over e-mail twice,
two weeks apart during April of 2017. The survey was administered through and data collected using REDCap electronic data
capture tools hosted at the University of Kentucky.4 Invitations
were sent out electronically via SCCM staff to all SCCM members of the CPP section, which includes pharmacist and nonpharmacist members. Pharmacist members of CPP practicing in
adult critical care settings were specifically invited to take the
survey and represent the target population of interest. Nonpharmacist members, or pharmacists practicing in a pediatric
critical care setting, were asked not to respond to the survey.

Statistical analysis
Data were analyzed with Stata (StataCorp. 2015. Stata
Statistical Software: Release 14. College Station, TX:
StataCorp LP). Categorical data from the survey are presented as proportions. Exploratory logistic regression analyses were undertaken to evaluate factors associated with the
following: selection of often or routinely (eg. >50% of the
time) for loading doses for all six clinical scenarios examined,
use of area-under-the-curve (AUC) as pharmacokinetic target parameter, and self-reported comfort with AUC calculations (ie. somewhat or extremely comfortable). Candidate
predictor variables identified a priori by the study team
thought to influence vancomycin dosing practices included:
region, practitioner years of experience, hospital type, hospital
size, and ICU type. Due to complete separation of variables in
some of the regression models, a penalized maximum likelihood regression model was used with the firthlogit package in
Stata.5-7 Output from regression models are presented as
odds ratios (OR) with 95% confidence intervals (CI). Twosided P-value <.05 was considered statistically significant.
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Table 1. Respondent demographics.
Number (%)

Practice Region
Midwestern United States

111/364 (30.5)

Southern United States

109/364 (30.0)

Western United States

74/364 (20.3)

Northeastern United States

60/364 (16.5)

Outside of United States

10/364 (2.7)

Institutional Setting
Academic medical center/urban

174/364 (47.8)

Community hospital/teaching/urban

89/364 (24.5)

Community hospital/non-teaching/urban

44/364 (12.1)

 Other (including government and rural
hospitals)

57/364 (15.6)

Institution Size
<250 beds

55/364 (15.1)

data from the section indicating that approximately 100 pharmacists practiced in pediatric critical care, we estimate that 1,400
of these pharmacists practiced in an adult ICU setting and would
be eligible for the survey. We received 364 responses, for an estimated response rate of 26%.

Respondent demographics
Respondent demographics are presented in Table 1.
Approximately half (48%) of respondents were from urban
academic medical centers. The two most frequent responses for
institutional bed size were 250-499 beds and 500-750 beds.
The large majority of respondents (>97%) were from the
United States with relatively similar representation from all
major geographic areas. A majority of pharmacists participating in the survey were clinical practitioners <5 years (33%) or
5-10 years (29%) removed from their terminal training. These
pharmacists most frequently practiced in a medical (30%) or
mixed medical/surgical (32%) ICU. Over 90% of pharmacist
respondents reported that a pharmacist rounded with the primary or intensivist team at least five days per week.

250-499 beds

119/364 (32.7)

500-750 beds

99/364 (27.2)

>750 beds

91/364 (25.0)

Vancomycin-related practices in respondent
institutions

35/364 (9.6)

Practice site characteristics regarding vancomycin are presented
in Table 2. The most common responses regarding what percentage of Staphylococcus aureus isolates were methicillin-resistant Staphylococcus aureus (MRSA) were either 20-39% (23% of
respondents) or 40-59% (34% of respondents). Vancomycin
was routinely reported as empiric therapy in hospital-acquired
infections by 67% of respondents. Fifty-five percent of respondents estimated the average duration of vancomycin use prior to
de-escalation when MRSA is not cultured as 48-72 hours. A
large majority of respondents (85%) reported that their institution reports the vancomycin minimum inhibitory concentrations for MRSA in the medical record.
Approximately one-third of respondents (31%) reported
their institution had no formal pharmacy consult order (or
pharmacy to dose protocol) to dose vancomycin. Another
31% of respondents reported that pharmacists may deviate
from the protocol as written, which they sometimes do (1050% of the time). The majority of pharmacists had a protocol
or other mechanism in place to order vancomycin serum concentrations (83%), laboratory monitoring (eg. basic metabolic
panel) (72%), or dose adjust according to vancomycin serum
concentration or renal function (78%); 18% of respondents
reported no formal mechanism for placing these orders,
requiring they be placed under a provider’s name pursuant to
a verbal or written order.
Twenty percent of respondents reported a protocol for vancomycin dosing in the setting of CRRT with a mechanism to
alert the pharmacist that CRRT is being initiated or discontinued; another 30% have a protocol with no mechanism to alert
the pharmacist of CRRT initiation or discontinuation. Most

Current Level of Training
 Current PGY2 specialty pharmacy resident
(any specialty)
 Practitioner less than 5 years out from
terminal training

121/364 (33.2)

 Practitioner 5-10 years out from terminal
training

104/364 (28.6)

 Practitioner more than 10 years out from
terminal training

99/364 (27.2)

Other

5/364 (1.4)

Primary Location or Service
Cardiothoracic ICU

20/364 (5.5)

Emergency Department

20/364 (5.5)

Medical ICU

109/364 (29.9)

Mixed Medical/Surgical ICU

115/364 (31.6)

Surgical/Trauma ICU

49/364 (13.5)

Other

51/364 (14.0)

Pharmacists Physically Round with the Primary or Intensivist
Team ⩾5 days/Week
Yes

332/364 (91.2)

Results

Survey response rate
The survey was delivered to 2,305 SCCM CPP members
(includes pharmacists and non-pharmacists) via e-mail using the
SCCM CPP section distribution list. Approximately 1,500 of
these members are pharmacists within the CPP section per the
SCCM demographic database. Based on internal demographic
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Table 2. Practice site characteristics and vancomycin-related demographics.

Number (%)

Institutional Protocol Description and Pharmacist Adherence
Pharmacists must adhere to the protocol as written and may not deviate
Pharmacists may deviate from the protocol as written, but I

rarelya

do

Pharmacists may deviate from the protocol as written, which I sometimesb do

8/364 (2.2)
36/364 (9.9)
111/364 (30.5)

Pharmacists may deviate from the protocol as written, which I oftenc do

63/364 (17.3)

Pharmacists may deviate from the protocol as written, and I routinelyd do

34/364 (9.3)

No formal protocol exists in my primary practice

112/364 (30.8)

Pharmacist Authorized to Order
Vancomycin levels

303/364 (83.2)

Laboratory tests for monitoring (eg. basic metabolic panel)

262/364 (72.0)

Dose adjustments based on vancomycin levels or renal function changes

283/364 (77.8)

Institutional Protocol for Vancomycin Dosing in Continuous Renal Replacement Therapy (CRRT)
Yes; but there is no mechanism to alert the pharmacist that CRRT is being initiated or discontinued

109/364 (29.9)

Yes; and there is a mechanism to alert the pharmacist that CRRT is being initiated or discontinued

71/364 (19.5)

No; and there is no mechanism to alert the pharmacist that CRRT is being initiated or discontinued

93/364 (25.6)

No; but there is a mechanism to alert the pharmacist that CRRT is being initiated or discontinued

51/364 (14.0)

Primary practice ICU does not utilize CRRT

40/364 (11.0)

Institutional Vancomycin Monitoring and Quality Assurance Programs
Quality assurance for percentage of vancomycin dosing regimens within goal target parameters

96/364 (26.4)

Real-time clinical decision support to notify pharmacists of acute changes in serum creatinine or urine output

90/364 (24.7)

Standardized definition of vancomycin-associated nephrotoxicity

27/364 (7.4)

None of these

159 (43.7)

Estimated Methicillin Resistant Staphylococcus aureus Isolates
20-39%

84/364 (23.1)

40-59%

122/364 (33.5)

60-80%

25/364 (6.9)

Other

32/364 (8.8)

Unknown/No specific antibiogram

101/364 (27.7)

Estimated Frequency of Empiric Vancomycin Therapy for Suspected Hospital-Acquired Infections
Rarelya

6/364 (1.6)

Sometimesb

16/364 (4.4)

Oftenc

99/364 (27.2)

Routinelyd

243/364 (66.8)

Estimated Average Duration of Vancomycin Use Prior to De-escalation when MRSA is Not Cultured
<2 days (<48 hours)

16/364 (4.4)

2-3 days (48-72 hours)

201/364 (55.2)

3-4 days (72-96 hours)

109/364 (30.0)

>4 days (>96 hours)
a<10%

of the time; b10-50% of the time; c51-90% of the time; d>90% of the time.

38/364 (10.4)

Flannery et al.
respondents (60%) did not use sustained low efficiency dialysis
(SLED) at their practice site.
When asked which vancomycin monitoring and quality assurance programs were offered at their institutions, respondents
indicated low rates of participation with regard to quality assurance for percentage of vancomycin dosing within a goal parameter (26%), clinical decision support to identify acute changes in
serum creatinine or urine output (25%), and standardized definition of vancomycin-associated nephrotoxicity (7%).

Respondent vancomycin dosing practices
Complete results are displayed in Table 3. With respect to scenario-based questions regarding use of vancomycin loading doses,
responses were mixed across scenarios. The percentage of pharmacists reporting either routinely or often (51-90% of the time)
using a loading dose for the surveyed conditions were as follows:
meningitis/CNS infection (84%), septic shock (79%), infective
endocarditis (75%), pneumonia in a mechanically ventilated
patient (69%), sepsis without shock (61%), and pneumonia in a
non-mechanically ventilated patient (54%). When respondents
were asked why they did not administer a loading dose at times
for a critically ill patient, the most common response was that
their assessment of the patient did not meet the definition of
severely ill (40%), followed by lack of clinical outcome data supporting the loading dose strategy (23%) and nephrotoxicity concerns (20%). Written comments by survey respondents suggested
other possible reasons, including physician concerns for nephrotoxicity and logistics of having to compound the loading dose in
the pharmacy versus using doses readily available in the patient
care area from automated dispensing cabinets.
Over 90% of respondents reported using actual body weight
for loading doses and maintenance doses in normal or underweight patients. For overweight or obese patients, 56% of respondents reported using actual body weight (41% used adjusted body
weight) for a loading dose and 45% of respondents reported using
actual body weight (51% used adjusted body weight) for maintenance dosing. The most commonly reported dose cap for a loading dose was 2,000 mg (45%) followed by 2,500 mg (28%), while
2,000 mg was the most commonly reported dose cap for maintenance dosing with the majority of respondents (75%).
The majority of respondents reported rarely assessing postloading dose concentrations, two level kinetics following the
first dose, and peak levels. The vast majority (87%) of respondents reported using trough values while 13% reported using
trough and AUC. When using trough values, 24% of respondents report that doses are held routinely pending evaluation of
the level, while 64% report doses are held pending evaluation
only in the setting of suspected acute kidney injury.
Pharmacists most commonly (92%) reported administering
vancomycin via intermittent infusion with the majority of pharmacists rarely using continuous infusion. Pharmacist perception
of their comfort level with AUC calculations was variable with
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intermittent infusion. The majority of respondents (62%) report
being not at all comfortable with AUC calculations for continuous infusions.
In exploratory regression models, respondents from larger
hospitals were overall less likely than smaller hospitals to report
consistently using loading doses often or routinely in all six scenarios presented: 250-499 beds (OR 0.4, 95% CI 0.2-0.9), 500750 beds (OR 0.4, 95% CI 0.2-0.9), and >750 beds (OR 0.4,
95% CI 0.2-0.8) [reference hospitals with <250 beds]. Europe
(OR 22.8, 95% CI 2.3-228.7) and Western US regions (OR 3.6,
95% CI 1.5-8.6) were more likely to report using AUC as a target
pharmacokinetic parameter for vancomycin use. No predictors
were identified for reported comfort with AUC calculations.

Discussion

Compliance with clinical practice guidelines is influenced by
many factors, notably the quality of the guidelines themselves,
users of the guidelines, and implementation context.8 Critical
care pharmacists were overall compliant with many of the 2009
guideline recommendations assessed except for a few particular
areas. Specifically, we observed inconsistent use of a loading dose,
dosing weight in obese patients, and quality improvement efforts
related to systematically monitoring vancomycin-associated
nephrotoxicity.
A survey of infectious disease pharmacist self-reported
adherence to the 2009 guidelines was previously published in
2013.3 Key variations in infectious disease pharmacist
reported practices from 2009 guideline recommendations
involved the recommendations around loading doses in seriously ill patients (only 42% reported always), use of actual
body weight to dose obese patients (40% reported sometimes;
52% reported always), and systematically monitoring nephrotoxicity with a standard definition to routinely identify and
report vancomycin-associated nephrotoxicity (34% reported
never; 35% reported sometimes).3 The authors of this study
noted it imperative to discern reasons for noncompliance to
the loading dose recommendation, particularly in severely ill
patients who may benefit and have altered pharmacokinetics.3
Our survey builds on prior work with a larger and more
diverse study sample and is unique by focusing on adult critical care pharmacists, includes survey items regarding sources
of practice variation related to vancomycin in critically ill
patients, and investigates reasons for pharmacists not adhering to certain 2009 guideline recommendations.
Our survey also identified variation in compliance with
loading dose recommendations; however, some pharmacists
report practicing differently in specific scenarios. In particular,
their assessment of severity of illness appears to be a large factor in administering a loading dose. Although some respondents may consider an ICU patient “severely ill” as the 2009
guidelines term it, this classification can be subjective.1 Lack
of clinical outcomes behind the 2009 recommendation for
loading doses (IIIB recommendation) and concerns of
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Table 3. Vancomycin dosing and monitoring strategies.
Frequency of loading dose recommendation by indication
Rarelya

Sometimesb

Oftenc

Routinelyd

Infective endocarditis

52/364 (14.3)

40/364 (11.0)

70/364 (19.2)

202/364 (55.5)

Meningitis/CNS infection

33/364 (9.1)

27/364 (7.4)

54/364 (14.8)

250/364 (68.7)

Pneumonia in a MV patient

51/363 (14.1)

60/363 (16.5)

75/363 (20.7)

177/363 (48.8)

Pneumonia in a non-MV patient

94/363 (25.9)

74/363 (20.4)

71/363 (19.6)

124/363 (34.2)

Sepsis with shock

40/364 (11.0)

38/364 (10.4)

68/364 (18.7)

218/364 (59.9)

Sepsis without shock

67/363 (18.5)

74/363 (20.4)

82/363 (22.6)

140/363 (38.6)

Pharmacist Reasoning When Choosing Not to Administer a Loading Dose
Lack of clinical outcome data supporting strategy

83/364 (22.8)

Nephrotoxicity concerns

73/364 (20.1)

Time required to infuse

13/364 (3.6)

The patient does not meet my definition of severely ill

146/364 (40.1)

Other

71/364 (19.5)

Most commonly used weight for dosing vancomycin
Actual body
weight

Ideal body
weight

Adjusted body
weight

Loading dose for normal/underweight patients

353/361 (97.8)

5/361 (1.4)

Loading dose for overweight/obese patients

201/361 (55.7)

12/361 (3.3)

148/361 (41.0)

Maintenance dose for normal/underweight patients

341/361 (94.5)

9/361 (2.5)

11/361 (3.1)

Maintenance dose for overweight/obese patients

162/361 (44.9)

16/361 (4.4)

183/361 (50.7)

3/361 (0.8)

Most commonly used dose cap
2000 mg per dose

2500 mg per
dose

3000 mg per dose

>3000 mg per
dose

No cap/max
dose

Loading dose

164/362 (45.3)

102/362 (28.2)

61/362 (16.9)

8/362 (2.2)

27/362 (7.5)

Maintenance dose

273/362 (75.4)

43/362 (11.9)

10/362 (2.8)

2/362 (0.6)

34/362 (9.4)

Use of the following strategies to assess vancomycin exposure and calculate further dosing
Rarelya

Sometimesb

Collect a post-loading dose level

322/361 (89.2)

29/361 (8.0)

3/361 (0.8)

7/361 (1.9)

Two-level kinetics after first dose

277/361 (76.7)

63/361 (17.5)

14/361 (3.9)

7/361 (1.9)

Collect peak levels

325/361 (90.0)

21/361 (5.8)

6/361 (1.7)

9/361 (2.5)

9/362 (2.5)

18/362 (5.0)

32/362 (8.8)

Collect trough levels

Oftenc

Routinelyd

303/362 (83.7)

Frequency of Doses Held Pending Level Evaluation When Trough Levels are Collected
Doses are held routinely (>90% of the time) pending level evaluation

87/362 (24.0)

Doses are held pending level evaluation only if kidney injury is suspected or known

233/362 (64.4)

Doses are held rarely (<10% of the time), even if kidney injury is suspected or known

42/362 (11.6)

Target Pharmacokinetic Dosing and Monitoring Parameter
Trough
AUC
Trough and AUC

314/363 (86.5)
2/363 (0.6)
47/363 (12.9)
(Continued)

Flannery et al.
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Table 3. (Continued)
Frequency of vancomycin dosing via method of administration
Rarelya

Sometimesb

Oftenc

Routinelyd

Intermittent infusion

10/364 (2.8)

11/364 (3.0)

8/364 (2.2)

335/364 (92.0)

Continuous infusion

342/363 (94.2)

16/363 (4.4)

3/363 (0.8)

2/363 (0.6)

Comfort level assessing vancomycin levels to calculate AUC
Not at all
comfortable

Somewhat
uncomfortable

Somewhat
comfortable

Extremely
comfortable

Intermittent infusion

134/363 (36.9)

54/363 (14.9)

100/363 (27.6)

75/363 (20.7)

Continuous infusion

223/362 (61.6)

59/362 (16.3)

49/362 (13.5)

31/362 (8.6)

a<10%

of the time; b10-50% of the time; c51-90% of the time; d>90% of the time; AUC, area-under-the-curve; CNS, central nervous system; MV, mechanically ventilated.

nephrotoxicity in an already at-risk patient population are also
commonly reported reasons for selectively administering loading doses.1 Concerns of nephrotoxicity with loading doses by
physician colleagues were also noted in the written responses
from pharmacist respondents in this survey and identified as
potential barriers to routinely using loading doses.
There were similar discrepancies between using actual body
weight for dosing in obese patients between the two surveys,
with a number of pharmacists in the current survey reporting use
of an adjusted body weight.3 The pharmacokinetics of vancomycin are known to be an area of controversy in obese patients.9
Due to the hydrophilicity of vancomycin and the increase in adipose tissue associated with obesity, its volume of distribution is
somewhat increased in obese patients. In addition, various dosing weights, including ideal body weight, total body weight, and
adjusted body weight, have been evaluated in estimating clearance of vancomycin with conflicting results.10 Given the complexity of critically ill, obese patients and a lack of strong evidence
for how to optimally dose vancomycin in these patients, it is not
surprising that our survey revealed such practice variation.
In both our survey and that of Davis et al.,3 there do seem to
be opportunities related to standardized definitions of vancomycin-associated nephrotoxicity and quality improvement programs
to track and monitor this complication.3 The possibility exists
that this is done within the context of antimicrobial stewardship
programs and surveyed ICU pharmacists may not be aware, but
this was reported as similarly low in the survey of infectious diseases pharmacists.3 Additionally, an opportunity may exist for
more institutions to implement CRRT alert triggers for pharmacists to increase or decrease doses, as appropriate.
The majority of critical care pharmacists surveyed rarely
employed continuous infusion dosing of vancomycin.
Interestingly, recent evidence suggests that continuous infusions
may be less nephrotoxic than intermittent infusions, particularly
in critically ill patients.11-13 Of paradoxical interest is that pharmacists were reportedly far less comfortable with AUC calculations for continuous infusions than with intermittent infusions,
given the AUC calculations for continuous infusion are much
simpler than for intermittent dosing. The varying comfort level

with AUC calculations in this survey demonstrates the importance of educational efforts that will be needed to employ
AUC-guided dosing in ICU patients on a larger scale, as is recommended by the revised vancomycin consensus guidelines
recently published in May of 2020.14
Our exploratory analysis found that respondents from
larger hospitals were generally less likely to report consistent
use of loading doses compared to respondents from hospitals
with <250 beds. While the exact reasoning for this is
unknown, it could be due to a relatively smaller number of
respondents from hospitals with <250 beds (15.1% of
respondents) or perhaps improved compliance with protocols
and guideline recommendations in smaller hospitals from this
survey. Additionally, our analysis suggests geographic variation in early adoption of AUC to guide vancomycin dosing,
with greater adoption in Western United States and Europe
at the time our survey was administered. Pharmacist education is clearly required for AUC dosing and monitoring given
the reported comfort rates. Although the pharmacokinetic
assumptions are fewer and calculations easier with continuous infusion, this may simply represent the unfamiliarity of
critical care pharmacists surveyed with employing continuous
infusions due to the low frequency of use identified.
Our study has important limitations to acknowledge. Only
SCCM CPP members participated in the study; thus, reported
behaviors from non-survey responders and non-SCCM CPP
members may be different. This survey only inquired about selfreported actions regarding vancomycin and may not reflect
actual actions from clinicians in their practice. Multiple respondents may have responded from the same institution, thus biasing
some reported metrics. Our response rate of 26% limited the
number of respondents that we were able to collect data from,
however, our study is more than twice as large as the prior study
of vancomycin dosing practices.3 Although Europe was identified as using AUC more than others in this survey, there were
few respondents from Europe, which may only represent a few
institutions and not be representative of European practice.
Finally, our survey was disseminated in the spring of 2017, and
we suspect additional centers have transitioned to AUC

Infectious Diseases: Research and Treatment 

8

Table 4. Comparisons between 2009 and 2020 vancomycin consensus guidelines relevant to survey of dosing practices.
Dosing
consideration

2009 vancomycin guidelines1

2020 revised consensus guidelines14

Monitoring
Parameters

“Trough serum vancomycin
concentrations are the most
accurate and practical method for
monitoring vancomycin
effectiveness.” (IIB)

“Trough-only monitoring, with a target of 15-20 mg/L, is no longer recommended
based on efficacy and nephrotoxicity data in patients with serious infections due
to MRSA” (A-II)
“In patients with suspected or definitive serious MRSA infections, an
individualized target of the AUC/MIC ratio of 400-600 (assuming a vancomycin
MIC of 1 mg/L) should be advocated to achieve clinical efficacy while improving
patient safety.” (A-II)

Loading Dose
and Weight

“In seriously ill patients, a loading
dose of 25-30 mg/kg (based on
actual body weight) can be used to
facilitate rapid attainment of target
trough serum vancomycin
concentration.” (IIIB)

“In order to achieve rapid attainment of targeted concentrations in critically ill
patients with suspected or documented serious MRSA infections, a loading dose
of 20-35 mg/kg can be considered for intermittent-infusion administration of
vancomycin.” (B-II)
“Loading doses should be based on actual body weight and not exceed 3000 mg.
More intensive and early therapeutic drug monitoring should also be performed in
obese patients.” (B-II)

Maintenance
Dosing Weight

“Vancomycin dosages should be
calculated on actual body weight.
For obese patients, initial dosing
can be based on actual body
weight and then adjusted based on
serum vancomycin concentrations
to achieve therapeutic levels.” (IIA)

“Initial maintenance doses of vancomycin can be computed using a population
pharmacokinetic estimate of vancomycin clearance and the target AUC in obese
patients. Empiric maintenance doses for most obese patients usually do not
exceed 4500 mg/day, depending on their renal function.” (B-II)

Continuous
Infusion

“Continuous infusion regimens are
unlikely to substantially improve
patient outcome when compared
with intermittent dosing.” (IIA)

“The pharmacokinetics of continuous infusion suggest that such regimens may be
a reasonable alternative to conventional intermittent-infusion dosing when the
AUC target cannot be achieved.” (B-II)

monitoring at this time given a signal of increased safety in terms
of kidney injury as well as anticipated (and actual) endorsement
of AUC guided dosing in recently released revised consensus
vancomycin guidelines.14-16 Although these revised guidelines
have been published since our survey, aside from recommending
a change from trough-based dosing to AUC and no longer
directly recommending actual body weight in maintenance dosing for obesity, many of the recommendations as they relate to
our survey remain similar between the 2009 and 2020 guidelines.1,14 Table 4 compares relevant dosing considerations from
our survey between the 2009 and 2020 guidelines.1,14 Our data
may serve as a benchmark in evaluating uptake of consensus
guideline recommendations, particularly against the backdrop of
showing a relatively low “early-adopter” rate for AUC-guided
dosing. In the context of newly revised consensus guidelines, we
also show continued room for improvement with the guideline
recommendation for loading doses, and demonstrate that a small
percentage of surveyed pharmacists are employing continuous
infusion. Finally, our survey also establishes the prevalence of
important dosing concepts that may not be presented as formal
guideline recommendations yet may reflect best practices in dosing vancomycin in critically ill patients, including electronic
alerts for CRRT initiation or discontinuation.

Conclusion

Critical care pharmacists’ reported practices regarding vancomycin are largely consistent with the 2009 vancomycin guideline
recommendations. Important areas of variation include use of
loading doses, dosing weights in obese patients, and quality

improvement efforts related to systematically monitoring vancomycin-associated nephrotoxicity. Further study in these particular areas may allow more definitive guideline recommendations
to help optimize vancomycin use in the critically ill.
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